Loading
institutionsInstitution
Seoul National University Hospital
Seoul National University Hospital is Korea's national university hospital and a top global enroller for gastric and lung cancer trials.
Overview
Seoul National University Hospital is Korea's national university hospital and, through the Seoul National University Cancer Hospital, ranks eighth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It is a top global enroller for gastric and lung cancer trials and has led work in gastric cancer on Claudin 18.2 and HER2, in non-small-cell lung cancer, and in radiotherapy. OnCo links it to gastric and gastro-oesophageal junction cancer and hepatocellular carcinoma, to the Korean Cancer Study Group, and to clinicians including Do-Youn Oh, Dong-Wan Kim, Seock-Ah Im and Tae-You Kim. As with other Korean centres, how its trial findings transfer to Western populations is a recurring question. Its gastric programme is the one to follow first.
Location
Seoul, KR
Type
hospital · Seoul National University
Website
Newsweek 2026 oncology rank
#8
OnCo score
#37 · 66 points (52 Newsweek + 0 NCI + 14 from 7 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Seoul National University Hospital, including child institutions. 1,612 works · 26,269 citations · 72% open access · 12% clinical trials · 1% reviews.
Oncology works per year
3522022
3212023
3482024
3372025
2542026
Most works
- Seock‐Ah Im81 works
- Jin‐Young Jang71 works
- Tae Min Kim55 works
- Do‐Youn Oh44 works
- Bhumsuk Keam42 works
- Jee Hyun Kim42 works
- Jin Won Kim38 works
- Yoo‐Seok Yoon36 works
- Jin‐Hyeok Hwang36 works
- Ho‐Seong Han32 works
Most cited
- Gastric cancer
- Lung cancer
Do-Youn Oh
Professor of Internal Medicine; gastrointestinal and hepatobiliary oncology
Biliary tract cancerPancreatic cancerImmunotherapy
Principal investigator of TOPAZ-1, the trial that added immunotherapy to first-line chemotherapy for bile duct cancer.
Dong-Wan Kim
Professor of Internal Medicine; thoracic oncology
Lung cancerALK and ROS1 fusionsTargeted therapy
Dong-Wan Kim is a thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.
Se-Hoon Lee
Professor of Internal Medicine; thoracic oncology and immunotherapy
Lung cancerImmunotherapySmall-cell lung cancer
A lung cancer oncologist who has helped test checkpoint inhibitors and next-generation ADCs in Korean patients.
Seock-Ah Im
Professor of Internal Medicine; breast medical oncology
Breast cancerCDK4/6 inhibitorsPremenopausal breast cancer
Led MONALEESA-7, which proved a CDK4/6 inhibitor extends survival in premenopausal breast cancer, and steers Korea's breast cancer trial network.
Tae-You Kim
Professor of Internal Medicine; gastrointestinal oncology and cancer genomics
Colorectal cancerGastric cancerCancer genomics
A GI oncologist and genomics researcher who leads precision oncology and colorectal cancer trials at Seoul National University.
Yung-Jue Bang
Professor Emeritus of Internal Medicine; Seoul National University Cancer Research Institute
Gastric cancerHER2Early-phase drug development
Principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive gastric cancer, and a founder of Korean phase 1 oncology.
Similar pages
- InstitutionTaipei Veterans General Hospital
Shares Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer.
- PersonHyung-Ho Kim
Shares Seoul National University Bundang Hospital, Gastric & gastro-oesophageal junction cancer.
- PersonJin Seok Ahn
Shares Korean Cancer Study Group, Non-small-cell lung cancer.
- InstitutionSeverance Hospital, Yonsei University
Shares Korean Cancer Study Group, Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS).
- InstitutionSamsung Medical Center
Shares Korean Cancer Study Group, Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Gastric & gastro-oesophageal junction cancer.
- Key paperBrigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)
Shares Dong-Wan Kim, Non-small-cell lung cancer.
- TermRadiation necrosis (brain)
Shares Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS).
- TrialToGA
Shares Yung-Jue Bang, Gastric & gastro-oesophageal junction cancer.